2022 World Conference on Lung Cancer (ePosters)-EP08.02-122. Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)

Pdf Summary

Capmatinib, a selective MET inhibitor, has shown promising efficacy in patients with non-small cell lung cancer (NSCLC) who have the mesenchymal-epithelial transition (MET) exon 14 skipping mutation. In this study, the authors conducted a retrospective analysis of data from an early access program to evaluate the real-world experience with capmatinib in these patients.<br /><br />The study included 81 patients with advanced MET exon 14-mutated NSCLC who were treated with capmatinib. The median age of the patients was 77 years, and 56% of them were women. The majority of patients (86%) had stage IV disease, and 27% had brain metastases.<br /><br />The objective response rate (ORR) to capmatinib was 58% in all patients, 68% in treatment-naïve patients, and 50% in pretreated patients. The median progression-free survival was 9.5 months, with slightly longer survival in treatment-naïve patients (10.6 months) compared to pretreated patients (9.1 months). The median overall survival was 18.2 months.<br /><br />In patients with measurable brain metastases, the intracranial ORR was 46%. Capmatinib was generally well-tolerated, with grade 3 treatment-related adverse events occurring in 13% of patients, including peripheral edema, elevated creatinine, and elevated liver enzymes.<br /><br />Overall, the study confirms the previously reported phase II data and demonstrates that capmatinib provides durable systemic and intracranial efficacy in patients with MET exon 14 skipping mutation-positive NSCLC. The findings support the use of capmatinib as a treatment option in this patient population.<br /><br />In conclusion, capmatinib shows promising efficacy and a manageable safety profile in patients with NSCLC harboring the MET exon 14 skipping mutation. Further research and clinical trials are needed to validate these findings and optimize the use of capmatinib in this patient population.

Asset Subtitle

Oliver Illini

Meta Tag

Speaker Oliver Illini

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Capmatinib

selective MET inhibitor

non-small cell lung cancer

NSCLC

mesenchymal-epithelial transition

MET exon 14 skipping mutation

retrospective analysis

real-world experience

objective response rate

progression-free survival